Health Condition 1: E113- Type 2 diabetes mellitus with ophthalmic complications
Conditions
Interventions
Intervention1: nepafenac 0.3% eye drops
: nepafenac 0.3% perioperatively.
once a day one drop in operated eye started one day prior before surgery and continue for 1 month in operated eye after surg
Sponsors
pondicherry institute of medical sciences
Eligibility
Inclusion criteria
Inclusion criteria: All diabetic patients in the age group 40yrs and above, will be undergoing routine cataract surgery.
Exclusion criteria
Exclusion criteria: • Preexisting macular diseases/ macular oedema • Recent intraocular surgery other than cataract surgery for 3 months • Intra operative complications during the surgery • Allergic or hypersensitive to NSAIDS, corticosteroids • Chronic and recurrent inflammatory eye diseases. • Use of any eye drops in last three months. • Diseases causing macular edema other than diabetes are age related macular degeneration, Retinal venous occlusion, Coats disease, Radiation retinopathy, choroidal tumors and retinitis pigmentosa Other drugs like chloroquine, tamoxifen and interferon can induce macular edema.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the effect of perioperative nepafenac 0.3% on central macular thickness after uneventful cataract surgery in diabetesTimepoint: Follow up day 1, day-7, day 28 | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the association of the effect of nepafenac (0.3%) with post cataract surgery visual acuity.Timepoint: Follow up day 1, day-7, day 28 | — |
Countries
India
Contacts
Public ContactAMOD HANSDAK
pondicherry institute of medical sciences
Outcome results
None listed